Alembic Pharmaceuticals Limited develops, manufactures, and markets pharmaceutical products in India and internationally. It offers active pharmaceutical ingredients and formulations. The company also provides branded and generic formulations in various therapeutic areas, such as cardiology, gynecology, gastrology, ophthalmology, dermatology, nephrology/urology, orthopedics, anti-infective, cold and cough, and anti-diabetic. In addition, it exports its products. Alembic Pharmaceuticals Limited was founded in 1907 and is headquartered in Vadodara, India.
Revenue of Alembic Pharmaceuticals Limited (APLLTD.NS)
Revenue in 2023 (TTM): $724.15 M
According to Alembic Pharmaceuticals Limited's latest financial reports the company's current revenue (TTM) is $724.15 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Alembic Pharmaceuticals Limited
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $724.15 M | $317.29 M | $113.94 M | $74.86 M | $72.96 M |
| 2022 | $669.71 M | $467.25 M | $84.25 M | $42.01 M | $40.52 M |
| 2021 | $619.85 M | $415.69 M | $109.55 M | $73.47 M | $61.72 M |
| 2020 | $625.11 M | $444.88 M | $185.72 M | $162.09 M | $135.83 M |
| 2019 | $532.2 M | $376.51 M | $140.31 M | $118.46 M | $98.2 M |
| 2018 | $451 M | $309.61 M | $104.61 M | $88.78 M | $69.23 M |
| 2017 | $359.58 M | $233.75 M | $77.03 M | $64.13 M | $48.89 M |
| 2016 | $358.99 M | $236.1 M | $73.62 M | $62.24 M | $47.77 M |
| 2015 | $361.95 M | $262.12 M | $118.87 M | $110.85 M | $85.24 M |
| 2014 | $238.14 M | $148.3 M | $47.31 M | $42.54 M | $33.52 M |
| 2013 | $215.64 M | $125.7 M | $42.94 M | $36.8 M | $27.9 M |
| 2012 | $176.9 M | $92 M | $31.43 M | $24.45 M | $19.58 M |
| 2011 | $173.73 M | $89.86 M | $27.51 M | $19.07 M | $15.42 M |
| 2010 | $142.05 M | $64.76 M | $18.99 M | $12.66 M | $10.12 M |